Scarica l'app Stockscreener
0.4024
53.61%
-0.4651
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché VCNX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.8675
Aprire:
$0.7
Volume 24 ore:
1,603
Relative Volume:
4.02
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-22.01M
Rapporto P/E:
-0.00471
EPS:
-85.4
Flusso di cassa netto:
$-18.31M
1 W Prestazione:
-53.61%
1M Prestazione:
-21.11%
6M Prestazione:
-81.55%
1 anno Prestazione:
-88.61%
Intervallo 1D:
$0.6617
$0.70
Intervallo di 1 settimana:
$0.6617
$0.70
Portata 52W:
$0.46
$1.13
Vaccinex Inc Stock (VCNX) Company Profile
Confronta VCNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VCNX
Vaccinex Inc
|
0.6617 | 0 | 0 | -22.01M | -18.31M | -85.40 |
|
ARGX
Argen X Se Adr
|
918.97 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.06 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
196.99 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
358.67 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.88 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| 2018-09-04 | Iniziato | Ladenburg Thalmann | Buy |
Vaccinex Inc Borsa (VCNX) Ultime notizie
Vaccinex (NASDAQ:VCNX) Trading 4.2% Higher – Time to Buy? - Defense World
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Vaccinex (NASDAQ:VCNX) Stock Price Down 5.7% – Time to Sell? - Defense World
Contrasting Vaccinex (NASDAQ:VCNX) & Palatin Technologies (PINK:PTNT) - Defense World
NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight - PR Newswire UK
What sets apart Novavax option from other COVID-19 vaccines - American Medical Association
Vaccinex, Inc. (NASDAQ:VCNX) Sees Significant Growth in Short Interest - Defense World
GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire
Senators from both parties grilled RFK Jr. on vaccines and more - NPR
Vaccine Development - Gates Foundation
TR | OpenAI4o Maintains Vaccinex(VCNX.US) With Hold Rating, Cuts Target Price to $0.5 - 富途牛牛
Head to Head Survey: Aerovate Therapeutics (NASDAQ:AVTE) vs. Vaccinex (NASDAQ:VCNX) - Defense World
Vaccinex (NASDAQ:VCNX) Trading 26.3% Higher – Here’s Why - Defense World
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - The Malaysian Reserve
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Huntington's Disease Market To Expand Significantly By 2034, States Delveinsight Report Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Menafn
Cannabinoid Agonist Clinical Trial Pipeline Appears Robust - GlobeNewswire
Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire
Vaccinex (NASDAQ:VCNX) Shares Down 2.7% – Time to Sell? - Defense World
Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
Vaccinex (NASDAQ:VCNX) Shares Down 2.4% – Time to Sell? - Defense World
Vaccinex presents promising cancer treatment data at ASCO By Investing.com - Investing.com India
Vaccinex to Report Promising New Clinical Results of Neoadjuvant - GuruFocus
Vaccinex presents promising cancer treatment data at ASCO - Investing.com
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025 - Nasdaq
Vaccinex to Report Promising New Clinical Results of - GlobeNewswire
Clinical Trial Success: New Drug Transforms Cold Tumors into Hot Immune Centers in Head and Neck Cancer - Stock Titan
Vaccinex (NASDAQ:VCNX) Stock Price Down 11.3% – Here’s What Happened - Defense World
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets - ACCESS Newswire
Vaccinex reports pepinemab boosts immune response in cancer - Investing.com
Vaccinex director resigns, no disagreement cited - Investing.com
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - Yahoo Finance
RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News
Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR
VCNX Stock Price and Chart — OTC:VCNX - TradingView
United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India
Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards - Quiver Quantitative
School Vaccine Mandates - Britannica
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire
Vaccinex inks multiple antibody discovery deals using ActivMAb By Investing.com - Investing.com UK
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 - GlobeNewswire
Vaccinex Stock Spikes On Promising Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Stocktwits
Vaccinex exercises warrants for proceeds of $6.2M - Seeking Alpha
Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns - TipRanks
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges - ACS Publications
Vaccinex says Alzheimer's candidate buoyed by additional early-stage data (NASDAQ:VCNX) - Seeking Alpha
VBI Vaccines to be delisted from Nasdaq following restructuring - Investing.com
Vaccinex Inc Azioni (VCNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.01%
0.53%
Capitalizzazione:
|
Volume (24 ore):